NCT02949388 is a Phase 2 clinical trial of 400 mg (200 mg BID) in Chronic Stable Plaque Psoriasis, sponsored by Innovation Pharmaceuticals, Inc..

Who is sponsoring NCT02949388?

NCT02949388 is sponsored by Innovation Pharmaceuticals, Inc..

What drugs are being tested in NCT02949388?

Interventions in NCT02949388: Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID).

What condition does NCT02949388 study?

NCT02949388 studies Chronic Stable Plaque Psoriasis.

Is NCT02949388 still recruiting?

NCT02949388 is currently completed. Last updated 9 February 2018.

Last reviewed 2018-02-09 · How we verify

NCT02949388

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double Blind, Parallel Group, Placebo-controlled Trial to Study the Efficacy and Safety of Two Oral Doses of Prurisol Administered Twice Daily for Twelve Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed Phase 2 Last updated 9 February 2018

What this trial tests

Phase 2 trial testing Placebo in Chronic Stable Plaque Psoriasis in 199 participants. Completed in 1 December 2017.

Timeline

1 November 2016

Primary endpoint
1 November 2017

1 December 2017

Quick facts

Lead sponsor	Innovation Pharmaceuticals, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	199
Start date	1 November 2016
Primary completion	1 November 2017
Estimated completion	1 December 2017
Sites	34 locations across United States

Drugs / interventions tested

Placebo
400 mg (200 mg BID) — full drug profile →
300 mg (150 mg BID) — full drug profile →

Conditions studied

Chronic Stable Plaque Psoriasis — all drugs for Chronic Stable Plaque Psoriasis →

Sponsor

Innovation Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Chronic Stable Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Proportion of participants achieving at least a 75% reduction from baseline in PASI score (PASI75) at Week 12
Time frame: 12 Weeks
The Psoriasis Area and Severity Index (PASI) quantifies the severity of psoriasis based on lesion severity and the percent of body surface area affected. It is a composite assessment, across body regions, reflected in a single score: 0 (no disease) to 72 (maximal disease).
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time frame: 16 Weeks
Reporting of Adverse Events measurements, and reporting of adverse events.

Sponsor's own description

This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Innovation Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT04784897 — A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 · Phase 2 · completed
NCT04240223 — A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers · Phase 1 · completed
NCT03042702 — A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer · Phase 2 · completed
NCT02324335 — Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02949388 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innovation Pharmaceuticals, Inc.
Last refreshed: 9 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02949388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing